2-bromo-1-methoxy-4-(4-ethylbenzyl)benzene | 882662-14-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-bromo-1-methoxy-4-(4-ethylbenzyl)benzene
• 英文别名: 2-Bromo-4-[(4-ethylphenyl)methyl]-1-methoxybenzene
• CAS: 882662-14-8
• 化学式: C₁₆H₁₇BrO
• 分子量: 305.214
• InChiKey: NNGGOUDIBKXYJC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.3
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-bromo-1-methoxy-4-(4-ethylbenzyl)benzene 在 三乙基硅烷 、 正丁基锂 、 三氟乙酸 作用下， 以 四氢呋喃 、 正己烷 、 二氯甲烷 为溶剂， 反应 1.67h， 生成
  参考文献：
  名称：

  C-Aryl 5a-carba-β-d-glucopyranosides as novel sodium glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes

  摘要：

  C-Aryl 5a-carba-beta-D-glucopyranose derivatives were synthesized and evaluated for inhibition activity against hSGLT1 and hSGLT2. Modifications to the substituents on the two benzene rings resulted in enhanced hSGLT2 inhibition activity and extremely high hSGLT2 selectivity versus SGLT1. Using the created superimposed model, the reason for the high hSGLT2 selectivity was speculated to be that additional substituents occupied a new space, in a different way than known inhibitors. Among the tested compounds, the ethoxy compound 5h with high hSGLT2 selectivity exhibited more potent and longer hypoglycemic action in db/db mice than our O-carbasugar compound (1) and sergliflozin (2), which could be explained by its improved PK profiles relative to those of the two compounds. These results indicated that 5h might be a promising drug candidate for the treatment of type 2 diabetes. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2012.04.053
• 作为产物：
  描述：

  3-溴-4-甲氧基苯甲醛 在 三乙基硅烷 、 三氟化硼乙醚 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 1.17h， 生成 2-bromo-1-methoxy-4-(4-ethylbenzyl)benzene
  参考文献：
  名称：

  C-Aryl 5a-carba-β-d-glucopyranosides as novel sodium glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes

  摘要：

  C-Aryl 5a-carba-beta-D-glucopyranose derivatives were synthesized and evaluated for inhibition activity against hSGLT1 and hSGLT2. Modifications to the substituents on the two benzene rings resulted in enhanced hSGLT2 inhibition activity and extremely high hSGLT2 selectivity versus SGLT1. Using the created superimposed model, the reason for the high hSGLT2 selectivity was speculated to be that additional substituents occupied a new space, in a different way than known inhibitors. Among the tested compounds, the ethoxy compound 5h with high hSGLT2 selectivity exhibited more potent and longer hypoglycemic action in db/db mice than our O-carbasugar compound (1) and sergliflozin (2), which could be explained by its improved PK profiles relative to those of the two compounds. These results indicated that 5h might be a promising drug candidate for the treatment of type 2 diabetes. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2012.04.053

文献信息

• Phosphonic Acid Derivatives and the Treating Agents of Diseases Related Hyperphosphatemia
  申请人：Tomiyama Hiroshi

  公开号：US20080119441A1

  公开（公告）日：2008-05-22

  This invention related to a series of new phosphonic acid derivatives having anti-hyperphosphatemia activity. (I) [wherein: A is selected from —(CH 2 ) n —, —CO—, —(CH 2 ) n —CO—(CH 2 ) m —, —(CH 2 ) n —CS—(CH 2 ) m — or branched alkylene group. B ring and C ring are selected from benzene ring, naphthalene ring, azulene ring or, heterocycle or fused heterocycle. D is —(CH 2 ) (n+1) —, —(CH2)-O—(CH 2 ) m —, —(CH 2 )—S(O) o —(CH 2 ) m —, —CF 3 or —(CH 2 ) n —NR 10 —(CH 2 ) m — (wherein: D ring is connected with the carbon atom composing C ring.) E is selected from oxygen atom or sulfur atom. P is phosphine atom. R 1 ˜R 7 (wherein R 1 and R 2 , R 4 and R 5 are joined together with neighbored carbon atom to form 5˜7 membered saturated or unsaturated hydrocarbon ring, or 5˜6 membered fused heterocycle. R 1 , R 2 and R 3 are not hydrogen atom if B ring is benzene ring.) may be the same or different and are substituents. R 8 and R 9 are may be the same or different and are substituents. R 10 is alkyl group. n and m are 0-10. o is 0-2.

  本发明涉及一系列具有抗高磷血症活性的新磷酸衍生物(I) [其中：A选自—(CH2)n—、—CO—、—( )n—CO—( )m—、—( )n—CS—( )m—或支链烷基。B环和C环选自苯环、萘环、蓝环或杂环或融合杂环。D选自—( )(n+1)—、—( )-O—( )m—、—( )—S(O)o—( )m—、—CF3或—( )n—NR10—( )m—（其中：D环与组成C环的碳原子相连）。E选自氧原子或硫原子。P为磷原子。R1˜R7（其中R1和R2，R4和R5与相邻的碳原子结合形成5˜7个成员的饱和或不饱和碳氢化合物环，或5˜6个成员的融合杂环。如果B环为苯环，则R1、R2和R3不是氢原子。）可能相同或不同，并且是取代基。R8和R9可能相同或不同，并且是取代基。R10是烷基。n和m为0-10。o为0-2。
• PHOSPHONIC ACID DERIVATIVE AND THERAPEUTIC AGENT FOR DISEASE IN WHICH HIGH PHOSPHATE LEVEL IN BLOOD PARTICIPATES
  申请人：Kotobuki Pharmaceutical Co., Ltd.

  公开号：EP1813620A1

  公开（公告）日：2007-08-01

  This invention related to a series of new phosphonic acid derivatives having anti- hyperphosphatemia activity. (I) [wherein: A is selected from -(CH2)n-, -CO-, -(CH2)n -CO-(CH2)m-, -(CH2)n -CS-(CH2)m- or branched alkylene group. B ring and C ring are selected from benzene ring, naphthalene ring, azulene ring or, heterocycle or fused heterocycle. D is -(CH2)(n+1)-, -(CH2)-O-(CH2)m-, -(CH2)-S(O)o-(CH2)m-, -CF3 or -(CH2)n-NR10-(CH2)m- (wherein: D ring is connected with the carbon atom composing C ring.). E is selected from oxygen atom or sufur atom. P is phosphine atom. R1 ~ R7 (wherein R1 and R2, R4 and R5 are joined together with neighbored carbon atom to form 5 ~ 7 membered saturated or unsaturated hydrocarbon ring, or 5 ~ 6 membered fused hetrocycle. R1, R2 and R3 are not hydrogen atom if B ring is benzene ring.) may be the same or different and are substituents. R8 and R9 are may be the same or different and are substituents. R10 is alkyl group. n and m are 0-10. o is 0-2.

  本发明涉及一系列具有抗高磷酸盐血症活性的新型膦酸衍生物。(I) 其中A 选自-(CH2)n-、-CO-、-( )n-CO-( )m-、-( )n-CS-( )m-或支链亚烷基。B 环和 C 环选自苯环、萘环、薁环或杂环或融合杂环。D 是-( )(n+1)-、-( )-O-( )m-、-( )-S(O)o-( )m-、-CF3 或-( )n-NR10-( )m-（其中：D 环与组成 C 环的碳原子相连）。E 选自氧原子或呋喃原子。P 是膦原子。R1 ~ R7（其中 R1 和 R2、R4 和 R5 与相邻的碳原子连接在一起，形成 5 ~ 7 个成员的饱和或不饱和烃环，或 5 ~ 6 个成员的融合三环。如果 B 环是苯环，则 R1、R2 和 R3 不是氢原子）可以相同或不同，并且是取代基。R8 和 R9 可以是相同或不同的取代基。R10 是烷基。
• US7691898B2
  申请人：——

  公开号：US7691898B2

  公开（公告）日：2010-04-06